PF-219,061
Chemical compound
![]() |
|
Clinical data | |
---|---|
Routes of
administration |
Nasal |
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard ( EPA ) | |
Chemical and physical data | |
Formula | C 13 H 19 N O 2 |
Molar mass | 221.300 g·mol −1 |
3D model ( JSmol ) | |
|
|
|
|
![]() ![]() |
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D 3 receptor . [1] [2] It was under development as a potential medication for the treatment of female sexual dysfunction . [3] [4] It did not advance into clinical trials. [5]
See also
References
- ↑ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, et al. (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters . 17 (24): 6691–6. doi : 10.1016/j.bmcl.2007.10.059 . PMID 17976986 .
- ↑ Brioni JD, Moreland RB (2006). "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies . 3 (4): 599. doi : 10.1016/j.ddstr.2006.10.006 .
- ↑ Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer [ permanent dead link ]
- ↑ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I (July 2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica; the Fate of Foreign Compounds in Biological Systems . 39 (7): 523–33. doi : 10.1080/00498250902893775 . PMID 19480558 . S2CID 26474660 .
- ↑ Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V (July 2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery . 11 (7): 641–64. doi : 10.1080/17460441.2016.1185413 . PMID 27135354 . S2CID 205917989 .